Physician profile
David Lustig
NPI 1093896367
$1,294.28
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $140 · 2021: $201 · 2022: $329 · 2023: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $228.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $389.15 | 2019-2023 | Myrbetriq |
| Pfizer INC. | $250.35 | 2022-2023 | |
| Endo Pharmaceuticals INC. | $146.41 | 2019-2023 | Xiaflex, Aveed |
| Janssen Biotech, INC. | $112.97 | 2019-2023 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $65.49 | 2019-2021 | |
| Boston Scientific Corporation | $52.19 | 2020 | |
| 180 Medical, INC. | $47.85 | 2023 | Cure Catheter, Self Cath |
| Urogen Pharma, INC. | $41.73 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $39.87 | 2022-2023 | Lynparza, Keytruda, Welireg |
| Myovant Sciences INC. | $37.79 | 2021 | |
| Laborie Medical Technologies Corp. | $24.93 | 2023 | |
| Smith+Nephew, INC. | $19.77 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $19.11 | 2022 | |
| Teleflex LLC | $16.49 | 2021 | |
| Varian Medical Systems, INC. | $15.16 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $15.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lustig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.